Received Mar 28, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | — | — |
HCP calling to report that her partner did not receive his 3rd dose of GARDASIL 9 that was due on 1/31/2025 because his insurance denied it since he is 46 years old. First and second GARDASIL 9 doses were administered appropriately.; No adverse effects reported.; This spontaneous report was received from a nurse and refers to a 46-year-old male patient. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On an unknown dates, the patient was vaccinated with the first and second dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) (strength, dose, formulation, route of administration, lot # and expiration date were not reported) as prophylaxis. Health care professional (HCP) called to report that her partner did not receive his third dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) that was due on 31-Jan-2025 because his insurance denied it since he was 46 years old (Incomplete course of vaccination). First and second doses were administered appropriately. No adverse effects reported (No adverse event).